Malignant News and Research

RSS

Scientists discover new approach for treating virus-induced lymphomas

Kaposi's sarcoma herpesvirus (KSHV) is a human tumor virus and an etiological agent for Kaposi's sarcoma and primary effusion lymphoma (PEL). PELs are aggressive lymphomas with reported median survival time shorter than six months after diagnosis.

19 Mar 2007

Blood pressure drug shows potential as lung cancer treatment

A hormone that is important in the control of blood pressure also shrinks lung cancer tumors in mice, suggesting a new way to prevent or treat the deadly cancer, according to scientists at Wake Forest University School of Medicine.

19 Mar 2007

Discovery of new cell involved with cancer

Scientists have discovered a new type of cell that appears to play a role in the development of cancer – a highly volatile, precancerous stem cell that can either remain benign or become malignant, depending upon environmental cues.

14 Mar 2007

Two novel therapies for multiple myeloma

Two novel biologics are currently being investigated for their potential benefit to multiple myeloma patients in separate ongoing clinical trials at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

14 Mar 2007

Scientists test 'secret weapon' against tumours

Cancer Research UK scientists in Glasgow have devised a new method of attacking cancer cells. They report the findings in the Journal of Clinical Investigation.

11 Mar 2007

Researchers discover a new mechanism that regulates stem cell division

Errors in stem cell division can give rise to tumours. By studying stem cells in the fruit fly, scientists at the Institute for Research in Biomedicine (IRB Barcelona) have identified one of the mechanisms that govern how these cells divide.

7 Mar 2007

New combined laparoscopy and colonoscopy procedure at NYPH/Weill Cornell

A small number of patients diagnosed with polyps in their large intestine have extensive or difficult-to-remove polyps, such as those that are flattened against the colon wall or in hard-to-reach places. As with all polyps that may develop into malignant cancers, they must be removed.

4 Mar 2007

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma

The addition of immunotherapy to chemotherapy for malignant skin cancer that has spread does not improve survival rates, researchers have found, and patients have more serious side effects, such as anemia, when the two treatments are combined.

1 Mar 2007

Cancer Research UK secures fenretinide orphan drug licence

A previously shelved drug could prove effective for treating a group of rare childhood cancers, and Cancer Research UK today announced it has been granted exclusive marketing rights for the drug in these indications by the European Commission and the Food and Drug Administration (FDA).

27 Feb 2007

Aspirin offers help for Barrett's esophagus

Researchers at Fred Hutchinson Cancer Research Center have found that people with the most-aggressive form of Barrett's esophagus, a precancerous condition that can lead to esophageal cancer, may benefit the most from preventive therapy with aspirin, ibuprofen and other nonsteroidal anti-inflammatory drugs, or NSAIDs.

27 Feb 2007

High blood glucose levels may signal an increased risk for cancer in women

The March journal also includes a study that found a link between high levels of persistent organic pollutants (POPs) in a person's bloodstream and insulin resistance, a precursor for type 2 diabetes.

27 Feb 2007

Publication of the National Mesothelioma Framework

People with a chest cancer related to exposure to asbestos will receive a boost today, as a new framework for improving their care is launched by Britain's Health Minister Rosie Winterton.

From Asthma + Lung UK 26 Feb 2007

Alternative, diet-based method of treating brain cancer

The biologists found that KetoCal, a commercially available high-fat, low-carbohydrate diet designed to treat epilepsy in children, can significantly decrease the growth of brain tumors in laboratory mice.

22 Feb 2007

New test identifies suitable lymphoma patients likely to respond to new therapy

Researchers at the Albert Einstein College of Medicine of Yeshiva University have discovered a genetic signature identifying cases of lymphoma that are uniquely susceptible to a newly developed molecular targeted therapy. As a result, physicians organizing clinical trials of the new therapy will be able to enroll patients who'll be most likely to benefit from it.

20 Feb 2007

Cancer cells 100 times more likely to genetically mutate

When cells become cancerous, they also become 100 times more likely to genetically mutate than regular cells, researchers have found. The findings may explain why cells in a tumor have so many genetic mutations, but could also be bad news for cancer treatments that target a particular gene controlling cancer malignancy.

20 Feb 2007

Survivors of childhood cancers have a ninefold increased risk of developing a secondary sarcoma

Treatments for childhood cancer have resulted in a current overall cure rate of over 70 percent. However, long-term survivors of childhood cancer are at a higher risk of developing a secondary cancer than the general population.

20 Feb 2007

Nanoparticles advance photodynamic therapy to kill tumor cells

Photodynamic therapy (PDT) is a powerful approach for destroying tumors, one that uses light and a light-sensitive chemical to rapidly kill cells.

20 Feb 2007

Avastin slows growth of gliomas

Avastin, a relatively new type of drug that shrinks cancerous tumors by cutting off their blood supply, can slow the growth of the most common and deadly form of brain cancer, a pilot study conducted at Duke University Medical Center has found.

20 Feb 2007

More evidence that inflammation can fuel cancer

As evidence mounts that the body's normally protective inflammation response can drive some precancerous tissues to become fully malignant, UCSF scientists report discovering an apparent trigger to this potentially deadly process.

19 Feb 2007

Cancer is a stem cell issue

There is an urgent reason to study stem cells: stem cells are at the heart of some, if not all, cancers. Mounting evidence implicates a clutch of rogue stem cells brandishing 'epigenetic' marks as the main culprits in cancer. Wiping out tumours for good, some biologists believe, depends on uprooting these wayward stem cells.

19 Feb 2007